Talaris Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TALS and buy or sell other stocks, ETFs, and their options commission-free!About TALS
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006.
CEOSandeep C. Kulkarni, MD
CEOSandeep C. Kulkarni, MD
Employees74
Employees74
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2021
Founded2021
Employees74
Employees74
TALS Key Statistics
Market cap31.04M
Market cap31.04M
Price-Earnings ratio-13.97
Price-Earnings ratio-13.97
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$48.27
52 Week high$48.27
52 Week low$11.56
52 Week low$11.56
Stock Snapshot
As of today, Talaris Therapeutics(TALS) shares are valued at $1.21. The company's market cap stands at 31.04M, with a P/E ratio of -13.97.
On 2025-12-05, Talaris Therapeutics(TALS) stock opened at —, reached a high of —, and a low of —.
The Talaris Therapeutics(TALS)'s current trading volume is 0.
During the past year, Talaris Therapeutics(TALS) stock moved between $11.56 at its lowest and $48.27 at its peak.
During the past year, Talaris Therapeutics(TALS) stock moved between $11.56 at its lowest and $48.27 at its peak.
People also own
Based on the portfolios of people who own TALS. This list is generated using Robinhood data, and it’s not a recommendation.